文献速递产科母胎医学

妊娠队列中丙型肝炎病毒抗体筛查:血清阳性率与危险因素

Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors.
PubMed 文献 · Obstet Gynecol · 2020-01-01

该研究纳入2012至2015年106842名孕妇进行HCV抗体筛查,血清阳性率为2.4例/1000名(95%CI 2.1-2.7)。病例对照分析显示注射吸毒、输血、伴侣HCV阳性、终生性伴侣超过3个及吸烟与HCV抗体阳性相关,上述任一危险因素复合指标检测敏感性达91%。

要点

  • 孕妇HCV抗体血清阳性率为2.4例/1000名。
  • 注射吸毒、输血及伴侣HCV阳性是强相关危险因素。
  • 复合危险因素筛查敏感性达91%,但现有筛查策略未识别全部风险因素。

核心结论

  • 该妊娠队列中HCV抗体血清阳性率较低,当前筛查危险因素未能完全识别HCV抗体阳性孕妇。

主要发现

  • HCV抗体血清阳性率为2.4例/1000名(95%CI 2.1-2.7)。
  • 注射吸毒调整比值比22.9(95%CI 8.2-64.0),输血3.7(95%CI 1.3-10.4),伴侣HCV阳性6.3(95%CI 1.8-22.6),终生性伴侣超过3个5.3(95%CI 1.4-19.8),吸烟2.4(95%CI 1.2-4.6)。
  • 上述任一危险因素复合指标检测HCV抗体的敏感性为75/82例(91%)。

关键数值与推荐

  • 病例组定义为Abbott ARCHITECT平台信号-截断值至少5。
  • 病例组评估RNA状态。

临床怎么用

  • 可考虑将注射吸毒、输血、伴侣HCV阳性、多个性伴侣及吸烟等复合危险因素用于识别HCV抗体阳性孕妇。
  • 有助于识别易发生母婴传播的新生儿。

局限性

  • 当前筛查危险因素未能识别所有HCV抗体阳性孕妇。
  • 研究纳入孕周小于23周且无已知多胎妊娠的孕妇,可能限制外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the prevalence of hepatitis C virus (HCV) antibody, evaluate current risk factors associated with HCV antibody positivity, and identify novel composite risk factors for identification of groups most likely to demonstrate HCV antibody seropositivity in an obstetric population from 2012 to 2015. METHODS: The Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network initiated an observational study of mother-to-child transmission of HCV in 2012 that included offering HCV antibody screening to their entire obstetric population. Women presenting for prenatal care before 23 weeks of gestation without a known multifetal gestation were eligible. For each woman who was HCV antibody-positive, two women at similar gestational age who were HCV antibody-negative were identified and included for comparison. Risk factors were evaluated by patient interview and chart review. Women in the case group were identified to have a signal-to-cutoff value of at least 5 on the Abbott ARCHITECT platform. RNA status was evaluated for women in the case group. RESULTS: Of 106,842 women screened for the HCV antibody, 254 had positive results. The HCV antibody seroprevalence rate was 2.4 cases per 1,000 women (95% CI 2.1-2.7). One hundred thirty-one women in the case group and 251 women in the control group were included in the case-control analysis. Factors associated with HCV antibody positivity included injection drug use (adjusted odds ratio [aOR] 22.9, 95% CI 8.2-64.0), blood transfusion (aOR 3.7, 95% CI 1.3-10.4), having a partner with HCV (aOR 6.3, 95% CI 1.8-22.6), more than three lifetime sexual partners (aOR 5.3, 95% CI 1.4-19.8), and smoking (aOR 2.4, 95% CI 1.2-4.6). A composite of any of these potential risk factors provided the highest sensitivity for detecting HCV antibody (75/82 cases, 91%). CONCLUSION: In this cohort, the seroprevalence of HCV antibody was low, and the current risk factors for HCV screening were not identified. These findings may be useful in defining new strategies for identifying mothers with the HCV antibody and the neonates susceptible to maternal transmission of HCV. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01959321.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Prasad M, Saade GR, Sandoval G, et al. Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors. Obstet Gynecol. 2020. PMID: 32168224. doi:10.1097/AOG.0000000000003754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。